Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This research study, called MK-3543-007, is looking at a new drug called Bomedemstat to treat Essential Thrombocythemia (ET). ET is a condition where your body makes too many blood platelets. This study aims to see if Bomedemstat is more effective and safer than Hydroxyurea, which is a common treatment for ET. They are particularly interested in people who haven't had treatment for their ET before and for whom treatment is recommended. The main goal is to find out if Bomedemstat can lead to a lasting positive response in managing the condition, better than Hydroxyurea. This could potentially offer a new treatment option for those living with ET.
En un coup d'œil
De quoi parle cette étude ?
This study is for people diagnosed with Essential Thrombocythemia (ET). ET is a rare, long-term condition where your body produces too many platelets, which are tiny blood cells that help stop bleeding. Having too many platelets can lead to problems like blood clots or bleeding. Some people with ET need treatment to lower their platelet count and reduce these risks.
The purpose of this study is to compare a new medicine called Bomedemstat with a long-standing treatment called Hydroxyurea. Hydroxyurea is a common drug used to reduce the number of platelets in people with ET. Researchers want to see if Bomedemstat works better and is just as safe, or safer, than Hydroxyurea. They are specifically focusing on people who are newly diagnosed with ET and haven't had treatment for it before, but for whom treatment is now recommended by their doctor.
The main thing the study wants to find out is if Bomedemstat can lead to a more stable and lasting improvement in your blood counts and overall condition compared to Hydroxyurea. If Bomedemstat proves to be more effective, it could become a new and important treatment option for people with ET in the future.
Points clés
- This study compares a new drug (Bomedemstat) with a standard treatment (Hydroxyurea) for ET.
- It's for people newly diagnosed with ET who need treatment.
- The main goal is to see if Bomedemstat offers a better, lasting response.
- Participation involves taking medication and regular health check-ups.
- You'll be closely monitored by medical professionals.
- Vous pouvez arrêter de participer à tout moment.
Qui peut être éligible ?
To join this study, you must have been diagnosed with Essential Thrombocythemia (ET) according to specific medical guidelines, and your doctor must recommend that you start treatment for it, regardless of your age or risk. Your bone marrow, which is where blood cells are made, must show only a mild level of scarring (Grade 0 or 1). It's also important that you haven't received any treatment for your ET in the past.
If you have HIV, it needs to be well-controlled with medication. If you have Hepatitis B, you should have been on antiviral treatment for at least a month, and the virus should not be detectable in your blood. For those with a history of Hepatitis C, the virus must also be undetectable.
However, you won't be able to join if you have certain other conditions. This includes any serious stomach or gut problems that might stop your body from absorbing medicines properly. Also, if you've had cancer in the past two years, unless it was fully cured. People with active infections needing strong medication, or those who have recently had major surgery (within the last 4 weeks or still recovering), also cannot take part. Additionally, if you have HIV and a history of specific related conditions called Kaposi's sarcoma or Multicentric Castleman's Disease, you cannot participate.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- I have been diagnosed with Essential Thrombocythemia (ET).
- My doctor has suggested I start treatment for my ET.
- I have never been treated for my ET before.
- I do not have any severe stomach or gut problems.
- I haven't had cancer in the last two years (unless fully cured earlier).
En quoi consiste la participation ?
If you decide to participate in this study, you will be assigned to receive either Bomedemstat or Hydroxyurea, or a dummy version (placebo) of one of these, though the main comparison is between the active drugs. Throughout the study, you will have regular visits to the clinic for medical check-ups, blood tests, and other assessments to monitor your health and how the treatment is working. This will involve physical examinations, discussions about your symptoms, and possibly additional tests like bone marrow biopsies at certain points. You will be given the study medication to take as instructed. The total length of your participation, including the treatment period and follow-up, will be explained in detail by the study team, but clinical trials usually involve ongoing monitoring for a significant period.
Risques et avantages potentiels
Locations (171)
- Palo Verde Cancer Specialists ( Site 0052)Code postal vérifiéGlendale, United States
- Los Angeles Cancer Network ( Site 0025)Code postal vérifiéGlendale, United States
- Stanford Cancer Center ( Site 0024)Code postal vérifiéPalo Alto, United States
- Exempla Lutheran Medical Center ( Site 0014)Code postal vérifiéGolden, États-Unis
- Yale University School of Medicine ( Site 0051)Code postal vérifiéNew Haven, États-Unis
- Parkview Research Center at Parkview Regional Medical Center ( Site 0006)Code postal vérifiéFort Wayne, United States
- University of Michigan ( Site 0003)Code postal vérifiéAnn Arbor, États-Unis
- Optum Care Cancer Center ( Site 0053)Code postal vérifiéLas Vegas, United States
- Levine Cancer Institute ( Site 0009)Code postal vérifiéCharlotte, États-Unis
- Duke University Health System (DUHS) ( Site 0012)Code postal vérifiéDurham, États-Unis
- Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 0013)Code postal vérifiéWinston-Salem, United States
- The Ohio State University Wexner Medical Center ( Site 0028)Code postal vérifiéColumbus, États-Unis
Questions fréquentes
Qu'est-ce que la Thrombocytémie Essentielle (TE) ?
ET is a condition where your body makes too many blood platelets, which are important for blood clotting. Too many platelets can lead to health problems.
What is Bomedemstat?
Bomedemstat is a new medicine being tested in this study to see if it can help control the high platelet count in people with ET.
What is Hydroxyurea?
Hydroxyurea is a standard medication already used to treat ET by helping to lower the number of platelets in the blood.
Will I know which treatment I'm receiving?
In some parts of the study, you might receive a placebo (dummy drug) or you might not know if you're getting Bomedemstat or Hydroxyurea. This is to ensure fair results.
Combien de temps l'étude durera-t-elle pour moi ?
The exact duration of your involvement will be discussed with you by the study team, as it can vary depending on the trial's design and your individual response.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.